Treatment 1 | Mechanism of Action | Results from RCT(s) | Guidelines Recommendation 2 |
De-prescribing of antihypertensive meds | Reduce orthostatic hypotension |
HR (syncope/pre-syncope)
0.40 (0.16- 1.00) 3 |
IIa (older w/ htn meds) |
Midodrine | Selective alpha-receptor agonist |
HR (time to 1st syncope) 0.59 (0.37-0.96) 4 |
IIb (younger & low BP) |
Fludrocortisone | Mineralocorticoid-like action |
HR (syncope; after 2wk of drug)
0.51 (0.28-0.89) 5 |
IIb (younger & low BP) |
Theophylline | Adenosine blockade | No RCT. In a case series, asystolic pause reduced from 9.6 to 1.1/yr. 6 | No recommendation |
Atomoxetine | NE transporter inhibition |
Episodes of syncope/presyncope at 3mos 2 (drug) vs 4 (placebo); p<0.0017 7 |
No recommendation |
Droxidopa | Synthetic NE prodrug | Symptoms improvement in neurogenic OH (assessed by questionnaire), P=0.0038 8 | No recommendation |
Trials | 1yr Recurrence Rate (PPM vs. No PPM) | Statistical Significance |
RCT: PPM vs no PPM 1 |
0% vs. 36% | P <0.001 |
RCT: PPM vs Atenolol 2 |
3% vs. 24% |
OR 0.13 95%CI 0.03-0.63 |
1. Brignole et al. Am J Cardiol. 1992 Apr 15;69(12):1039-43. | 2. Ammirati et al. Circulation. 2001 Jul 3;104(1):52-7. |
Trials | 1yr Recurrence Rate (PPM ON vs OFF) | HR (95%CI) |
ISSUE 3 1 | 25% vs. 37% | 0.43 (0.04-0.81) |
BIOSYNC CLS 2 | 19% vs. 53% | 0.23 (0.11-0.47) |
1. Brignole et al. Circulation. 2012 May 29;125(21):2566-71. | 2. Brignole et al. Eur Heart J. 2021 Feb 1;42(5):508-516. |
Trials | Inclusions | Yoga Protocol | Mean Syncope Episodes
(Yoga vs. Control) |
|
6wks | 1yr | |||
RCT, N=97 | Reflex syncope 3+/yr, age 12-60 yr |
Instructed;
breathing & postures exercises 60mins/d x 5/wk |
0.8 vs 1.8
P <0.001 |
1.1 vs 3.8
P <0.001 |
RCT, N=55 | Reflex syncope 2+/3mo, age 15-70yr |
0.17 vs 0.45 P =0.04 |
0.70 vs 2.52 P <0.01 |